The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's weight-loss pill, orforglipron, to be marketed as Foundayo. This once-daily oral medication targets the GLP-1 hormone and has shown promising results in clinical trials, with patients losing between 12% and 15% of their body weight. Foundayo will be available starting April 6 at a price of $149 per month, aligning it with Novo Nordisk's pricing for its GLP-1 medications. This approval re-establishes Lilly's competition with Novo Nordisk, which previously led the market with its injectable GLP-1 drugs, including Ozempic and Wegovy. Analysts note that Foundayo's flexible dosing—allowing it to be taken at any time of day—could influence its market uptake compared to Novo's Wegovy, which requires specific timing with meals. Shares of Lilly rose 6% following the announcement, while Novo's shares dipped slightly. Analysts estimate that oral medications like Foundayo could capture around 20% of the weight-loss market by 2030, although injectables are expected to remain the more effective option for weight loss.